
Myomo Cash Flow 2025-2011 | MYO
Brief overview of Myomo's cash movements
The comparison covers five available annual reports between 2021 and 2025.
At the end of the period, operations consumed -$14.5 million rather than generating cash. This profile calls for caution.
Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.
Operating cash flow margin improved from -68.9% to -35.5%. The quality of revenue growth strengthened.
An additional $3.7 million became tied up in estimated working capital, equal to 9% of revenue.
Overall picture
Myomo's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow Myomo
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-14.5 M | -3.29 M | -6.17 M | -10.2 M | -9.55 M | -9.03 M | -10.3 M | -9.61 M | -6.15 M | -3.2 M | - | - | - | - | - |
Depreciation & Amortization |
859 K | 206 K | 164 K | 193 K | 146 K | 105 K | 95.1 K | 69.7 K | 11.4 K | 7.73 K | - | - | - | - | - |
Accounts Payables |
1.51 M | 1.17 M | 1.07 M | 570 K | 723 K | 180 K | 450 K | 427 K | 265 K | - | - | - | - | - | - |
Accounts Receivables |
4.1 M | 3.83 M | 2.38 M | 1.9 M | 1.96 M | 925 K | 424 K | 382 K | 297 K | - | - | - | - | - | - |
Total Inventories |
3.12 M | 3.17 M | 1.8 M | 1.4 M | 808 K | 707 K | 440 K | 256 K | 201 K | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Myomo
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-2.2 M | - | - | -2.68 M | - | - | - | -3.25 M | - | - | - | -1.82 M | - | -7.77 M | - | -2.32 M | - | -7.72 M | - | -2.11 M | - | -7.88 M | -6.11 M | -2.45 M | - | -7.7 M | -5.41 M | -3.12 M | - | -7.09 M | -4.61 M | -2.27 M | - | -4.61 M | -2.75 M | -1.16 M | - | -2.3 M | -984 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
292 K | - | - | 158 K | - | - | - | 29.7 K | - | - | - | 48.6 K | - | 144 K | - | 45.6 K | - | 95.2 K | - | 23.3 K | - | 79.7 K | 53 K | 26.4 K | - | 70.7 K | 45.1 K | 21.6 K | - | 48.8 K | 28.9 K | 14.6 K | - | 6.98 K | 4.55 K | 2.17 K | - | 5.86 K | 4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
1.81 M | 1.62 M | 2.51 M | 2.49 M | 1.17 M | 1.3 M | 1.37 M | 829 K | 1.07 M | 1.22 M | 767 K | 907 K | 570 K | 879 K | - | 1.01 M | 723 K | 624 K | 612 K | 714 K | 180 K | 180 K | 180 K | 180 K | 450 K | 450 K | 450 K | 450 K | 427 K | 427 K | 427 K | 427 K | 265 K | 265 K | 265 K | 265 K | 311 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
4.82 M | 5.29 M | 7.05 M | 4.66 M | 3.83 M | 3.73 M | 2.53 M | 1.68 M | 2.38 M | 2.52 M | 1.64 M | 1.55 M | 1.9 M | 1.6 M | - | 1.69 M | 1.96 M | 2.22 M | 1.13 M | 765 K | 925 K | 925 K | 925 K | 925 K | 424 K | 424 K | 424 K | 424 K | 382 K | 382 K | 382 K | 382 K | 297 K | 297 K | 297 K | 297 K | 115 K | 115 K | 115 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
3.55 M | 3.65 M | 4.13 M | 3.37 M | 3.17 M | 3.38 M | 2.6 M | 2.39 M | 1.8 M | 1.48 M | 1.34 M | 1.57 M | 1.4 M | 1.48 M | - | 1.03 M | 808 K | 644 K | 729 K | 794 K | 707 K | 707 K | 707 K | 707 K | 440 K | 440 K | 440 K | 440 K | 256 K | 256 K | 256 K | 256 K | 201 K | 201 K | 201 K | 201 K | 82.4 K | 82.4 K | 82.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Myomo, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
InspireMD
NSPR
|
$ 0.65 | -3.68 % | $ 41.8 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Profound Medical Corp.
PROF
|
$ 7.38 | 1.79 % | $ 223 M | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
$ 3.48 | -1.14 % | $ 148 M | ||
|
AVITA Medical
RCEL
|
$ 4.4 | -2.0 % | $ 123 M | ||
|
AxoGen
AXGN
|
$ 42.21 | 2.08 % | $ 1.94 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
$ 62.84 | -2.33 % | $ 9.54 B | ||
|
Smith & Nephew plc
SNN
|
$ 31.56 | -2.46 % | $ 27.4 B | ||
|
Tactile Systems Technology
TCMD
|
$ 28.17 | -0.11 % | $ 644 M | ||
|
TELA Bio
TELA
|
$ 0.73 | 2.83 % | $ 34.3 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Tandem Diabetes Care
TNDM
|
$ 19.5 | 2.58 % | $ 1.33 B | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Viemed Healthcare
VMD
|
$ 11.67 | -0.77 % | $ 454 M | ||
|
ClearPoint Neuro
CLPT
|
$ 14.94 | 2.47 % | $ 423 M | ||
|
Varex Imaging Corporation
VREX
|
$ 11.19 | 1.08 % | $ 463 M | ||
|
Avanos Medical
AVNS
|
$ 24.99 | - | $ 1.16 B | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
Inogen
INGN
|
$ 6.45 | 0.47 % | $ 172 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.36 | 3.08 % | $ 22.4 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.82 | -1.39 % | $ 13.9 M | ||
|
Integer Holdings Corporation
ITGR
|
$ 121.21 | 20.18 % | $ 4.21 B | ||
|
Beyond Air
XAIR
|
$ 5.28 | -2.68 % | $ 43.8 B | ||
|
Xtant Medical Holdings
XTNT
|
$ 0.43 | -0.6 % | $ 60 M | ||
|
LivaNova PLC
LIVN
|
$ 80.14 | -1.12 % | $ 4.37 B | ||
|
NanoVibronix
NAOV
|
- | - | $ 1.08 M |